Abiraterone and Increased Survival in Metastatic Prostate Cancer
Open accessThe DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index; 17 of the 40 sources its claims cite were checked for support.
Abstract
BACKGROUND: Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS: We randomly assigned, in a 2:1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS: After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the preplanned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group. CONCLUSIONS: The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 7 Not checked · 36 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“A unique molecular alteration described in castration-resistant prostate cancer is the up-regulation of androgen biosynthesis enzymes, leading to an increase in intratumoral androgen concentrations, which can exceed the levels measured in the blood.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Not checked yetcites [7] matched to “Gene Expression Analysis of Human Prostate Carcinoma during Hormonal Therapy Identifies Androgen-Responsive Genes and Mechanisms of Therapy Resistance” (2004) source
- Partly supportedcites [8] matched to “Increased Expression of Genes Converting Adrenal Androgens to Testosterone in Androgen-Independent Prostate Cancer” (2006) sourceExperimental — accuracy not yet measured
The Abstract and Discussion (page numbers unavailable) report increased expression of androgen-metabolism genes in androgen-independent prostate cancer and propose enhanced intracellular conversion of adrenal androgens as a mechanism for substantial tissue androgen levels. The paper does not state that intratumoral androgen concentrations exceed blood levels; its tissue comparison is with normal or nonneoplastic prostate. (LLM, conf=0.88)
- Partly supportedcites [9] matched to “Maintenance of Intratumoral Androgens in Metastatic Prostate Cancer: A Mechanism for Castration-Resistant Tumor Growth” (2008) sourceExperimental — accuracy not yet measured
The Results report up-regulated transcripts for androgen-biosynthesis enzymes in castration-resistant metastases and say tumor testosterone concentrations exceeded equivalent concentrations in the patients’ serum. But the Discussion says the processes sustaining intratumoral androgens have yet to be determined and proposes enzyme modulation as a possible mechanism; it does not establish that the up-regulation caused the higher concentrations. No page number is available in our copy. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Treatment with abiraterone acetate did not appear to increase the risk of metabolic changes or symptoms associated with chronic androgen deprivation.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Could not verifycites [42] matched to “Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy: Observational Study of Veterans With Prostate Cancer” (2010) sourceExperimental — accuracy not yet measured
The Methods passage describes GnRH agonists, orchiectomy, and oral antiandrogens, but does not identify abiraterone acetate as a treatment studied. The Results and Discussion address diabetes and cardiovascular outcomes for those treatments, not metabolic changes or symptoms during abiraterone treatment. Searches for “abiraterone acetate” and the claimed metabolic changes and symptoms found no passage addressing that specific claim. (LLM, conf=0.77)
- Could not verifycites [43] matched to “Androgen-Deprivation Therapy in Prostate Cancer and Cardiovascular Risk: A Science Advisory From the American Heart Association, American Cancer Society, and American Urological Association: Endorsed by the American Society for Radiation Oncology” (2010) sourceExperimental — accuracy not yet measured
The 'Adverse Effects of ADT' section describes metabolic changes associated with androgen-deprivation therapy generally, but does not assess abiraterone acetate. Searches for 'abiraterone acetate' and 'symptoms associated with chronic androgen deprivation' found no passage addressing whether abiraterone increases those risks. (LLM, conf=0.76)
- Not checked yetcites [44] matched to “Management of Complications of Prostate Cancer Treatment” (2008) source
- Not checked yetcites [45] matched to “Contribution of Androgen Deprivation Therapy to Elevated Osteoclast Activity in Men with Metastatic Prostate Cancer” (2004) source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“These results show that continued androgen-receptor signaling contributes to disease progression”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Not checked yetcites [2] matched to “Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis” (2005) source
- Supportedcites [10] matched to “Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?” (2009) source
The Abstract of the Attard et al. (2009) Cancer Cell preview states that 'clinical data from abiraterone acetate and MDV-3100 confirm continued androgen receptor (AR) addiction in a significant proportion of castration-resistant prostate cancers,' and the Main Text adds that 'the growth of the majority of cancer cells in many patients with cancers recurring after castration remains dependent on the AR signaling axis,' with nuclear AR expression persisting in metastases and AR transcriptional activity described as 'required for prostate cancer progression' (Hormone-Driven Oncogenesis). The conclusion reiterates that a significant proportion of CRPC finds AR signaling 'a hard habit to break.' This covers the claim's substance — persistent AR signaling contributing to progression in metastatic CRPC — though the source phrases it as addiction/persistence in a significant proportion rather than in all patients. (LLM, conf=0.88)
- Not checked yetcites [31] matched to “Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling” (2011) source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In phase 1–2 trials, treatment with abiraterone acetate, either as a single agent or in combination with low-dose glucocorticoids such as prednisone, resulted in significant antitumor activity among both patients with progressing castration-resistant prostate cancer who had not received chemotherapy and those who had received chemotherapy.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Abstract > CONCLUSIONS
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
The Abstract Patients and Methods (p.1) and Introduction state this phase I/II trial enrolled castrate, chemotherapy-naive CRPC patients only, and the PATIENTS AND METHODS > Patients section explicitly excludes 'Patients who had previously received cytotoxic chemotherapy or a radiopharmaceutical'; the antitumor activity figures (≥50% PSA decline in 67% of 42, RECIST partial responses in 9/24, Abstract Results) therefore apply solely to the chemotherapy-naive population. The low-dose glucocorticoid component is supported in that the study prospectively added dexamethasone 0.5 mg/d at progression and reversed resistance in 33% of patients (Abstract Results; Discussion). What this source does not support is the post-chemotherapy arm of the claim: the Discussion mentions only that a phase III study of abiraterone plus prednisone in docetaxel-treated patients 'is now being evaluated,' with no results reported here. (LLM, conf=0.85)
- Supportedcites [16] matched to “Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids” (2010) source
In the body of this correspondence (section 'Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids'), the authors open by summarising the three multicenter phase I/II studies of abiraterone acetate in CRPC (chemotherapy-naive Ryan et al, and the post-docetaxel Reid et al and Danila et al studies listed in their References) and state that their prechemotherapy data 'confirmed the significant antitumor activity of abiraterone acetate' (radiologic regression, PSA and circulating tumour cell decreases), that the combination with low-dose corticosteroids (dexamethasone/prednisone) gave 'durable secondary tumor responses... in 25% of patients', and close by affirming 'the significant and durable antitumor activity and the satisfactory safety profile of abiraterone acetate at 1,000 mg daily'. Low-dose prednisone is explicitly named. This source is correspondence reporting/summarising those trials rather than a primary trial report, but it states every element attributed to it here. (LLM, conf=0.82)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy is a single phase I trial, and it confirms significant antitumor activity (PSA declines ≥30%/≥50% in 66%/57% of 21 patients, RECIST partial responses in 5 of 8) in chemotherapy-naive CRPC (Antitumor Activity section), with low-dose dexamethasone 0.5 mg/d added at progression reinducing sensitivity in 4 of 15 patients (Reversal of Resistance section). However, the post-chemotherapy arm and the phase II results are not reported here: the Discussion (B2 C1 C2) states only that these findings 'have led to the phase II evaluation... in both chemotherapy-naïve and docetaxel-treated patients... data from this evaluation will be reported soon,' and the Patients section explicitly excluded men previously treated with chemotherapy. Prednisone is not the glucocorticoid used in this paper (dexamethasone was), so the 'phase 1-2 trials... both chemotherapy-naive and post-chemotherapy' scope is not carried by this source. (LLM, conf=0.78)
- Supportedcites [18] matched to “Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therapy in Patients With Docetaxel-Treated Castration-Resistant Prostate Cancer” (2010) source
Our copy covers every element of the summary sentence. The Abstract and Results describe this phase II trial of abiraterone acetate 1,000 mg daily with low-dose prednisone 5 mg twice daily in 58 men with progressive metastatic CRPC after docetaxel failure, reporting significant antitumor activity (confirmed ≥ 50% PSA decline in 36%, partial responses in 4/22 RECIST-evaluable patients, ECOG improvement in 28%). The Introduction states that 'Significant antitumor effects were seen in patients with progressive CRPC who had not received prior chemotherapy' (citing the phase I trial, Attard 2008, and the phase II chemo-naive AA-plus-prednisone study, Ryan 2009) and that 'In a separate trial, we showed significant antitumor effects of abiraterone acetate (AA) monotherapy in this patient group' (post-docetaxel, Reid/Danila), i.e. activity with AA alone as well as with low-dose steroid, in both chemotherapy-naive and post-chemotherapy settings. The Discussion likewise frames this as 'the second trial showing the activity of AA in patients ... who have progressed on chemotherapy.' (LLM, conf=0.85)
- Partly supportedcites [19] matched to “Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate” (2010) sourceExperimental — accuracy not yet measured
Our copy directly supports the trial/patient-population part: the Conclusion (p. 1) and DISCUSSION (p. 5) state that abiraterone acetate 1,000 mg had significant antitumor activity in post-docetaxel CRPC (≥50% PSA declines in 51%, with radiologic, symptomatic and CTC support), and the INTRODUCTION (p. 2) plus DISCUSSION (p. 6) report the authors' own phase I and phase II pre-docetaxel (chemotherapy-naïve) studies as showing abiraterone 'well tolerated and active'. What our copy does not support is the efficacy attribution to a glucocorticoid combination: low-dose glucocorticoids (and eplerenone) appear only as management of mineralocorticoid-excess toxicities (Treatment and Procedures, p. 3; Safety, p. 5; DISCUSSION, p. 6), the trial itself was single-agent abiraterone, and prednisone co-administration is mentioned only as the design of the subsequent phase III trial (DISCUSSION, p. 5), not as a phase 1-2 activity result. (LLM, conf=0.78)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) supports only part of the sentence: the DISCUSSION (p. 1) states 'Abiraterone acetate has significant activity in patients with CRPC, as evidenced by a PSA response rate of 58% in this phase I trial,' and RESULTS/Efficacy report confirmed ≥50% PSA declines in 55%-58% of men with chemotherapy-naïve progressive CRPC, including 47% of those with prior ketoconazole. However, this is a single-agent phase I dose-escalation trial only — 'Prior chemotherapy for prostate cancer was not allowed' (Major Eligibility Criteria), and the DISCUSSION states the exclusion of prior-chemotherapy patients was intentional, with 'ongoing studies...evaluating abiraterone in patients with both chemotherapy-refractory and chemotherapy-naïve CRPC,' so the post-chemotherapy activity attributed here is not from this paper. Glucocorticoids were also not part of the tested regimen: prednisone/corticosteroids were used reactively to manage mineralocorticoid toxicity, and the authors only 'suggest that a low dose of a corticosteroid, such as prednisone, be administered with abiraterone acetate in future studies'; the DISCUSSION notes 'the impact of concurrent prednisone on response proportion and durability...is not known.' (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The safety profile observed in the group of patients who received abiraterone acetate was similar to that observed in earlier clinical studies.”
§ Abiraterone and Increased Survival in Metastatic Prostate Cancer > Discussion
What the sources say
- Partly supportedcites [15] matched to “Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer” (2009) sourceExperimental — accuracy not yet measured
Our copy details the safety profile of the 1,000-mg abiraterone acetate group in RESULTS > Safety Profile (secondary mineralocorticoid excess: hypokalemia 88%, hypertension 40%, fluid overload 31%, managed with eplerenone; grade 3 transaminase elevation in 2 patients; grade 1 headaches/joint aches) and calls it 'effective, well-tolerated' in the DISCUSSION, so the first half of the claim is grounded. However, no passage states that this profile was 'similar to that observed in earlier clinical studies'; the only cross-study safety remarks compare abiraterone with ketoconazole trials (grade >=3 toxicities in up to 30% of patients, all requiring hydrocortisone) and explicitly caution that 'it is difficult to make any comparisons.' The prior abiraterone phase I experience is referenced (ref 15) as having identified the 1,000-mg dose, not as a matched safety comparison. The comparative/similarity element is therefore unsupported by our copy. (LLM, conf=0.68)
- Partly supportedcites [17] matched to “Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven” (2008) sourceExperimental — accuracy not yet measured
Our copy documents this trial's own safety profile (Safety and Tolerability: dose escalation to 2,000 mg achieved, no treatment-related grade 3 or 4 toxicities, hypertension/hypokalemia/edema controlled with eplerenone; DISCUSSION: toxicities predominantly due to secondary mineralocorticoid excess), and the INTRODUCTION notes that first-in-man studies reported abiraterone acetate was safe when given daily for 12 days to men with prostate cancer. However, no passage compares the two or states the profiles were similar; the only 'similar' statement in the paper is of hypertension incidence across dose levels within this study, and the DISCUSSION frames this as 'the first study to demonstrate that selective and continuous inhibition of CYP17 is safe', with the earlier clinical experience being short-course dosing in noncastrate men. The comparative element of the claim ('similar to that observed in earlier clinical studies') is therefore not supported by this source. (LLM, conf=0.65)
- Partly supportedcites [20] matched to “Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy” (2010) sourceExperimental — accuracy not yet measured
Ryan et al. (2010) describe their own safety findings as acceptable and consistent with expected CYP17 inhibition (DISCUSSION: 'The adverse event and steroid endocrine profiles were consistent with anticipated outcomes of selective CYP17 inhibition'; well tolerated through 1,000 mg/d with no MTD and no toxicity difference by prior ketoconazole exposure, DISCUSSION). However, the only external comparison our copy makes is to a CONCURRENT study, not to earlier clinical studies: RESULTS (Dose Escalation) states 'These findings paralleled a concurrent study with abiraterone acetate.' The claim's framing of similarity to 'earlier clinical studies' is therefore not supported by this source. (LLM, conf=0.68)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
23 more claims · 3 with their cited sources checked
Create a free account to see all 50 claims and to verify the 23 references still open.
- It may state two separate claims as one. 10
- The quote only partly states this claim. 3
- Probably not a substantial claim. 11
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Abiraterone acetate is an orally active prodrug of abiraterone, a potent P450c17 inhibitor (316) indicated for treatment of castration-resistant prostate cancer (317, 318).”
From Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society* Clinical Practice Guideline (2018) · cites this paper as [317]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Although improvements in clinical outcomes have been observed with novel therapies [20–31], their approval has resulted in uncertainties on optimal treatment sequencing, and utilization of these treatments is limited, demonstrating the need for improved real-world treatment practices.”
From Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey (2025) · cites this paper as [20]
In the citing paper
“Abiraterone is a potent CYP17A1 inhibitor that efficiently inhibits testosterone production120 and is used to treat prostate cancer.”
From Management challenges and therapeutic advances in congenital adrenal hyperplasia (2022) · cites this paper as [120]
In the citing paper
“Additionally, androgen biosynthesis from C21 precursors can be reduced by CYP17A1 inhibition with abiraterone as successfully applied for the treatment of CRPC (Attard et al., 2008, de Bono et al., 2011, James et al., 2017).”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as de Bono et al., 2011
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 2×
“Arthralgia 215 (27) 33 (4) 0 89 (23) 16 (4) 0”
Self-citationSipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 3×
“Bone pain 194 (25) 42 (5) 2 (<1) 110 (28) 25 (6) 4 (1)”
de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241 · cited 1×
“Fluid retention and edema 241 (31) 16 (2) 2 (<1) 88 (22) 4 (1) 0”
Self-citationde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182 · cited 2×
“Nausea 233 (30) 12 (2) 1 (<1) 124 (32) 10 (3) 0”
Self-citationDevelopment of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases
Daut, R. L., Cleeland, C. S., & Flanery, R. C. (1983) · Pain · doi:10.1016/0304-3959(83)90143-4 · Cited by 1,562
Cited by
Items 201–300 of 1,010
Harouaka, R., Kang, Z., Zheng, S.-Y., & Cao, L. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.10.004 · Cited by 195
“Subsequently, a phase III study showed that abiraterone is effective in improving overall survival for castration-resistant prostate cancer patients (de Bono et al., 2011).”
BackgroundMichaelson, M. D., Oudard, S., Ou, Y.-C., Sengeløv, L., Saad, F., Houede, N., Ostler, P., Stenzl, A., Daugaard, G., Jones, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5268 · Cited by 193
“Abiraterone acetate, in combination with prednisone, improved PFS and OS in docetaxelpretreated patients and was recently reported to extend PFS in chemotherapy-naive patients as well.(5,47) Three other compounds, enzalutamide, cabazitaxel, and radium-223 dichloride, have also demonstrated survival benefit in mCRPC pa…”
BackgroundSelf-citationKulkarni, H. R., Singh, A., Schuchardt, C., Niepsch, K., Sayeg, M., Leshch, Y., Wester, H.-J., & Baum, R. P. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.170167 · Cited by 192
Ferraldeschi, R., Welti, J., Luo, J., Attard, G., & de Bono, J. S. (2015) · Oncogene · doi:10.1038/onc.2014.115 · Cited by 192
Danila, D. C., Anand, A., Sung, C. C., Heller, G., Leversha, M. A., Cao, L., Lilja, H., Molina, A., Sawyers, C. L., Fleisher, M., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.07.011 · Cited by 192
“The randomized phase 3 trial of AA plus prednisone (COU-AA-301), which included the study of CTC enumeration as an efficacy-response surrogate biomarker for survival, met the primary end point of an improvement in survival in postchemotherapytreated CRPC and led to the FDA approval of the drug for this indication [1].”
BackgroundSelf-citationAlternative splicing in prostate cancer
Paschalis, A., Sharp, A., Welti, J. C., Neeb, A., Raj, G. V., Luo, J., Plymate, S. R., & de Bono, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0085-0 · Cited by 190
Crawford, E. D., Higano, C. S., Shore, N. D., Hussain, M., & Petrylak, D. P. (2015) · Journal of Urology · doi:10.1016/j.juro.2015.06.106 · Cited by 190
Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
Efstathiou, E., Titus, M., Tsavachidou, D., Tzelepi, V., Wen, S., Hoang, A., Molina, A., Chieffo, N., Smith, L. A., Karlou, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7675 · Cited by 189
“All patients had bone-metastatic CRPC.”
BackgroundResultInfluentialSelf-citationZylla, D., Gourley, B. L., Vang, D., Jackson, S., Boatman, S., Lindgren, B., Kuskowski, M. A., Le, C., Gupta, K., & Gupta, P. (2013) · Cancer · doi:10.1002/cncr.28345 · Cited by 188
“studies did not include an analysis of opioid requirement.(1,16,19,33,34) We have demonstrated that morphineinduced breast tumor growth in mice was accompanied”
BackgroundPerturbation Biology: Inferring Signaling Networks in Cellular Systems
Molinelli, E. J., Korkut, A., Wang, W., Miller, M. L., Gauthier, N. P., Jing, X., Kaushik, P., He, Q., Mills, G., Solit, D. B., et al. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003290 · Cited by 187
Lolli, C., Caffo, O., Scarpi, E., Aieta, M., Conteduca, V., Maines, F., Bianchi, E., Massari, F., Veccia, A., Chiuri, V. E., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00376 · Cited by 188
Reina-Campos, M., Linares, J. F., Duran, A., Cordes, T., L'Hermitte, A., Badur, M. G., Bhangoo, M. S., Thorson, P. K., Richards, A., Rooslid, T., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.018 · Cited by 186
Molecular events in neuroendocrine prostate cancer development
Wang, Y., Wang, Y., Ci, X., Choi, S. Y. C., Crea, F., Lin, D., & Wang, Y. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00490-0 · Cited by 182
Immune Infiltration and Prostate Cancer
Strasner, A., & Karin, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00128 · Cited by 184
von Eyben, F. E., Roviello, G., Kiljunen, T., Uprimny, C., Virgolini, I., Kairemo, K., & Joensuu, T. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3895-x · Cited by 184
Poruchynsky, M. S., Komlodi-Pasztor, E., Trostel, S., Wilkerson, J., Regairaz, M., Pommier, Y., Zhang, X., Kumar Maity, T., Robey, R., Burotto, M., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416418112 · Cited by 182
Szmulewitz, R. Z., Peer, C. J., Ibraheem, A., Martinez, E., Kozloff, M. F., Carthon, B., Harvey, R. D., Fishkin, P., Yong, W. P., Chiong, E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.4381 · Cited by 182
“PSA changes while receiving treatment were consistent with prior studies.(2,3) At 12 weeks, there were only three of 34 evaluable patients (9%) with primary PSA progression (post-treatment PSA increase as best response) within the STD group.”
InfluentialYadav, M. P., Ballal, S., Sahoo, R. K., Dwivedi, S. N., & Bal, C. (2019) · American Journal of Roentgenology · doi:10.2214/ajr.18.20845 · Cited by 182
Scosyrev, E., Messing, E. M., Mohile, S., Golijanin, D., & Wu, G. (2012) · Cancer · doi:10.1002/cncr.26392 · Cited by 180
Androgen action and metabolism in prostate cancer
Green, S. M., Mostaghel, E. A., & Nelson, P. S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.046 · Cited by 181
Chen, E. J., Sowalsky, A. G., Gao, S., Cai, C., Voznesensky, O., Schaefer, R., Loda, M., True, L. D., Ye, H., Troncoso, P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1220 · Cited by 182
“CYP17A1 inhibitors can thereby markedly further decrease the levels of testosterone and DHT, and the CYP17A1 inhibitor abiraterone has been approved by the FDA for treatment of CRPC (7, 8).”
Armstrong, A. J., Eisenberger, M. A., Halabi, S., Oudard, S., Nanus, D. M., Petrylak, D. P., Sartor, A. O., & Scher, H. I. (2012) · European Urology · doi:10.1016/j.eururo.2011.11.009 · Cited by 181
“These include the androgen synthesis inhibitor abiraterone acetate (AA) [1], the immunotherapeutic sipuleucel-T [2], and the taxoid cabazitaxel [3].”
BackgroundSelf-citationAntonarakis, E. S., Heath, E. I., Smith, D. C., Rathkopf, D., Blackford, A. L., Danila, D. C., King, S., Frost, A., Ajiboye, A. S., Zhao, M., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-314 · Cited by 180
“We demonstrate that, in men with metastatic chemotherapy-untreated CRPC, lowdose itraconazole (200mg/day) lacks significant antitumorefficacy, whereas high-dose itraconazole (600 mg/day) may havemodest clinical activity, as suggested by longer PPFS and PFS times than in historical data [25].”
BackgroundInfluentialGeorge, D. J., Sartor, O., Miller, K., Saad, F., Tombal, B., Kalinovský, J., Jiao, X., Tangirala, K., Sternberg, C. N., & Higano, C. S. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.12.019 · Cited by 179
Self-citationAndrogen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting
Antonarakis, E. S., Armstrong, A. J., Dehm, S. M., & Luo, J. (2016) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2016.17 · Cited by 177
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer
Wadosky, K. M., & Koochekpour, S. (2016) · Oncotarget · doi:10.18632/oncotarget.10901 · Cited by 174
“These novel treatments were hailed at the time for increasing overall survival of CRPCa patients to a greater extent than the chemotherapeutic agent docetaxel (Table 2) [56-59].”
BackgroundInfluentialSydes, M. R., Parmar, M. K., Mason, M. D., Clarke, N. W., Amos, C., Anderson, J., de Bono, J., Dearnaley, D. P., Dwyer, J., Green, C., et al. (2012) · Trials · doi:10.1186/1745-6215-13-168 · Cited by 174
Redirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
Li, Z., Alyamani, M., Li, J., Rogacki, K., Abazeed, M., Upadhyay, S. K., Balk, S. P., Taplin, M.-E., Auchus, R. J., & Sharifi, N. (2016) · Nature · doi:10.1038/nature17954 · Cited by 171
Puhr, M., Hoefer, J., Eigentler, A., Ploner, C., Handle, F., Schaefer, G., Kroon, J., Leo, A., Heidegger, I., Eder, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0989 · Cited by 171
“The development of novel drugs that target androgen receptor (AR) signaling, such as abiraterone (1, 2) and enzalutamide (3, 4), has expanded the limited therapeutic options for treatment of prostate cancer.”
BackgroundAttard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T., Taplin, M.-E., & collaborators, O. B. O. T. P. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9827 · Cited by 173
“of bone metastases 0 13 (10) 12 (10) 1-4 37 (29) 44 (35) 5-9 24 (19) 22 (18) 10-20 22 (17) 19 (15) .”
Self-citationCYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents
Yin, L., & Hu, Q. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2013.274 · Cited by 172
Nyquist, M. D., Li, Y., Hwang, T. H., Manlove, L. S., Vessella, R. L., Silverstein, K. A. T., Voytas, D. F., & Dehm, S. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308587110 · Cited by 171
“The majority of men who progress on abiraterone and enzalutamide display rising serum levels of the AR-regulated prostatespecific antigen gene, indicating that these tumors remain ARdriven (13, 15, 43).”
BackgroundEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
(2014) · New England Journal of Medicine · doi:10.1056/nejmc1410239 · Cited by 172
Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary
Kluetz, P. G., Pierce, W., Maher, V. E., Zhang, H., Tang, S., Song, P., Liu, Q., Haber, M. T., Leutzinger, E. E., Al-Hakim, A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2665 · Cited by 170
“org Clin Cancer Res; 20(1) January 1, 2014 11”
BackgroundInfluentialARv7 Represses Tumor-Suppressor Genes in Castration-Resistant Prostate Cancer
Cato, L., de Tribolet-Hardy, J., Lee, I., Rottenberg, J. T., Coleman, I., Melchers, D., Houtman, R., Xiao, T., Li, W., Uo, T., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.008 · Cited by 167
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
Glickman, M. S., & Sawyers, C. L. (2012) · Cell · doi:10.1016/j.cell.2012.02.015 · Cited by 168
Chi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv594 · Cited by 167
“Abiraterone–prednisone significantly prolonged overall survival (OS) compared with prednisone alone [6, 7].”
BackgroundMethodInfluentialSelf-citationTargeting the Androgen Signaling Axis in Prostate Cancer
Dai, C. S., Dehm, S. M., & Sharifi, N. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00433 · Cited by 194
Halabi, S., Lin, C.-Y., Small, E. J., Armstrong, A. J., Kaplan, E. B., Petrylak, D., Sternberg, C. N., Shen, L., Oudard, S., de Bono, J., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt280 · Cited by 165
“001 Missing 17 (3) 6 (2) 6 (1) Time since diagnosis, y 4.”
Self-citationMetastatic prostate cancer remains incurable, why?
Dong, L., Zieren, R. C., Xue, W., de Reijke, T. M., & Pienta, K. J. (2019) · Asian Journal of Urology · doi:10.1016/j.ajur.2018.11.005 · Cited by 164
Hofman, M. S., Emmett, L., Violet, J., Y. Zhang, A., Lawrence, N. J., Stockler, M., Francis, R. J., Iravani, A., Williams, S., Azad, A., et al. (2019) · BJU International · doi:10.1111/bju.14876 · Cited by 165
Structural and functional biology of aldo-keto reductase steroid transforming enzymes
Penning, T. M., Wangtrakuldee, P., & Auchus, R. J. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00089 · Cited by 164
Al Nakouzi, N., Le Moulec, S., Albigès, L., Wang, C., Beuzeboc, P., Gross-Goupil, M., de La Motte Rouge, T., Guillot, A., Gajda, D., Massard, C., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.04.015 · Cited by 164
“In patients with mCRPC, two AR axis inhibitors have improved overall survival (OS): abiraterone, a CYP17 inhibitor [3–5], and enzalutamide, an AR inhibitor [6].”
BackgroundSelf-citationClos‐Garcia, M., Loizaga‐Iriarte, A., Zuñiga‐Garcia, P., Sánchez‐Mosquera, P., Rosa Cortazar, A., González, E., Torrano, V., Alonso, C., Pérez‐Cormenzana, M., Ugalde‐Olano, A., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1470442 · Cited by 164
Patient-derived xenografts and organoids model therapy response in prostate cancer
Karkampouna, S., La Manna, F., Benjak, A., Kiener, M., De Menna, M., Zoni, E., Grosjean, J., Klima, I., Garofoli, A., Bolis, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21300-6 · Cited by 161
Bahl, A., Oudard, S., Tombal, B., Özgüroĝlu, M., Hansen, S., Kocak, I., Gravis, G., Devin, J., Shen, L., de Bono, J. S., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt194 · Cited by 163
AR Signaling and the PI3K Pathway in Prostate Cancer
Crumbaker, M., Khoja, L., & Joshua, A. (2017) · Cancers · doi:10.3390/cancers9040034 · Cited by 162
Clinical and molecular features of treatment‐related neuroendocrine prostate cancer
Akamatsu, S., Inoue, T., Ogawa, O., & Gleave, M. E. (2018) · International Journal of Urology · doi:10.1111/iju.13526 · Cited by 163
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Baca, S. C., Takeda, D. Y., Seo, J.-H., Hwang, J., Ku, S. Y., Arafeh, R., Arnoff, T., Agarwal, S., Bell, C., O’Connor, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22139-7 · Cited by 158
Quinn, D. I., Tangen, C. M., Hussain, M., Lara, P. N., Goldkorn, A., Moinpour, C. M., Garzotto, M. G., Mack, P. C., Carducci, M. A., Monk, J. P., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70294-8 · Cited by 161
Asangani, I. A., Wilder-Romans, K., Dommeti, V. L., Krishnamurthy, P. M., Apel, I. J., Escara-Wilke, J., Plymate, S. R., Navone, N. M., Wang, S., Feng, F. Y., et al. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0472 · Cited by 158
“Secondgeneration antiandrogen therapies, such as abiraterone and enzalutamide, have become standard-of-care treatments for mCRPC (5, 6).”
BackgroundSong, B., Park, S.-H., Zhao, J. C., Fong, K.-W., Li, S., Lee, Y., Yang, Y. A., Sridhar, S., Lu, X., Abdulkadir, S. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122367 · Cited by 158
“Recent use of new-generation antiandrogens such as abiraterone and enzalutamide (Enz) further prolonged patient lives for several months to a year (2, 3), yet resistance inevitably develops, ultimately leading to death.”
BackgroundNext-generation Sequencing of Advanced Prostate Cancer Treated with Androgen-deprivation Therapy
Rajan, P., Sudbery, I. M., Villasevil, M. E. M., Mui, E., Fleming, J., Davis, M., Ahmad, I., Edwards, J., Sansom, O. J., Sims, D., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.08.011 · Cited by 157
“The current focus of novel therapies for CRPC is the targeting of renewed AR signalling [2,3,19].”
BackgroundFizazi, K., Jones, R., Oudard, S., Efstathiou, E., Saad, F., de Wit, R., De Bono, J., Cruz, F. M., Fountzilas, G., Ulys, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5119 · Cited by 157
Self-citationProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Horwich, A., Parker, C. C., de Reijke, T. M., & Kataja, V. V. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt208 · Cited by 181
“These include abiraterone acetate [39] and enzalutamide [40].”
BackgroundWelti, J. C., Sharp, A., Yuan, W., Dolling, D. I., Rodrigues, D. N., Figueiredo, I., Gil, V., Neeb, A., Clarke, M., Seed, G., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3571 · Cited by 157
“Clin Cancer Res; 24(13) July 1, 2018 Clinical Cancer Research 3154”
BackgroundInfluentialRydzewska, L. H. M., Burdett, S., Vale, C. L., Clarke, N. W., Fizazi, K., Kheoh, T., Mason, M. D., Miladinovic, B., James, N. D., Parmar, M. K. B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.07.003 · Cited by 155
Self-citationBasch, E., Autio, K. A., Ryan, C. J., Mulders, P., Shore, N. D., Kheoh, T. S., Fizazi, K. S., Logothetis, C. J., Rathkopf, D. E., Smith, M. R., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70424-8 · Cited by 157
Self-citationMechanisms of Therapeutic Resistance in Prostate Cancer
Nakazawa, M., Paller, C., & Kyprianou, N. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0568-7 · Cited by 154
Metastatic Prostate Cancer: Treatment Options
Achard, V., Putora, P. M., Omlin, A. G., Zilli, T., & Fischer, S. (2021) · Oncology · doi:10.1159/000519861 · Cited by 164
Jin, L., Garcia, J., Chan, E., de la Cruz, C., Segal, E., Merchant, M., Kharbanda, S., Raisner, R., Haverty, P. M., Modrusan, Z., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0314 · Cited by 153
“Prostate cancer cell growth is driven by activity of the androgen receptor (AR), and therapies that target the androgen signaling axis have been highly successful in treatment of the disease (1, 2).”
BackgroundDecline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer
Lorente, D., Olmos, D., Mateo, J., Bianchini, D., Seed, G., Fleisher, M., Danila, D. C., Flohr, P., Crespo, M., Figueiredo, I., et al. (2016) · European Urology · doi:10.1016/j.eururo.2016.05.023 · Cited by 169
“both trials have been published elsewhere [2,14,21].”
Self-citationRodríguez-Bravo, V., Pippa, R., Song, W.-M., Carceles‐Cordon, M., Dominguez-Andres, A., Fujiwara, N., Woo, J., Koh, A. P., Ertel, A., Lokareddy, R. K., et al. (2018) · Cell · doi:10.1016/j.cell.2018.07.015 · Cited by 174
McKay, R. R., Ye, H., Xie, W., Lis, R. T., Calagua, C., Zhang, Z., Trinh, Q., Chang, S. L., Harshman, L. C., Ross, A. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01777 · Cited by 157
“of positive biopsy (range) 7 (2-24)† 8 (3-12)”
InfluentialMisawa, A., Takayama, K., Urano, T., & Inoue, S. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.718536 · Cited by 159
Den, R. B., Feng, F. Y., Showalter, T. N., Mishra, M. V., Trabulsi, E. J., Lallas, C. D., Gomella, L. G., Kelly, W. K., Birbe, R. C., McCue, P. A., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.04.052 · Cited by 148
Ware, K. E., García-Blanco, M. A., Armstrong, A. J., & Dehm, S. M. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0470 · Cited by 166
“…the responsiveness and survival benefits observed with newer AR-targeted agents such as enzalutamide and abiraterone acetate, which were developed to more potently inhibit AR signaling in the face of castrate levels of testosterone (Scher et al. 2010, 2012, de Bono et al. 2011, Ryan et al. 2013).”
InfluentialPretorius, E., Africander, D. J., Vlok, M., Perkins, M. S., Quanson, J., & Storbeck, K.-H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0159867 · Cited by 148
Fossati, N., Trinh, Q., Sammon, J. D., Sood, A., Larcher, A., Sun, M., Karakiewicz, P. I., Guazzoni, G. F., Montorsi, F., Briganti, A., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.08.056 · Cited by 153
“It is noteworthy that LT, in patients with predicted CSM risk<30%, was associated with a roughly 20% increase in survival at 3 yr, which is significantly higher than the survival benefit offered by any of the novel agents recently developed and approved to treat castration-resistant mPCa [7,8].”
Schalken, J. A., & Fitzpatrick, J. M. (2015) · British Journal of Urology · doi:10.1111/bju.13123 · Cited by 168
Nelson, P. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1300 · Cited by 153
Pezaro, C. J., Omlin, A. G., Altavilla, A., Lorente, D., Ferraldeschi, R., Bianchini, D., Dearnaley, D., Parker, C., de Bono, J. S., & Attard, G. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.044 · Cited by 147
“Cabazitaxel is one of six survival-prolonging therapies now available for men with metastatic castration-resistant prostate cancer (CRPC) [1–6].”
Self-citationAnticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms
Alexandre, J., Moslehi, J. J., Bersell, K. R., Funck‐Brentano, C., Roden, D. M., & Salem, J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.04.009 · Cited by 157
Cai, C., He, H. H., Gao, S., Chen, S., Yu, Z., Gao, Y., Chen, S., Chen, M. W., Zhang, J., Ahmed, M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.11.008 · Cited by 151
Sonpavde, G., Matveev, V. B., Burke, J. M., Caton, J. R., Fleming, M. T., Hutson, T. E., Galsky, M. D., Berry, W. R., Karlov, P., Holmlund, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr555 · Cited by 157
Self-citationAlumkal, J. J., Sun, D., Lu, E., Beer, T. M., Thomas, G. V., Latour, E., Aggarwal, R., Cetnar, J., Ryan, C. J., Tabatabaei, S., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1922207117 · Cited by 147
Self-citationA Targetable GATA2-IGF2 Axis Confers Aggressiveness in Lethal Prostate Cancer
Vidal, S. J., Rodríguez-Bravo, V., Quinn, S. A., Barrueco, R. R., Lujambio, A., Williams, E. S., Sun, X., de la Iglesia-Vicente, J., Lee, A., Readhead, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.11.013 · Cited by 158
Prostate cancer: ESMO Consensus Conference Guidelines 2012
Horwich, A., Hugosson, J., de Reijke, T. M., Wiegel, T., Fizazi, K. S., Kataja, V. V., Parker, C. C., Bellmunt, J., Berthold, D., Bill‐Axelson, A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds624 · Cited by 164
Self-citationFitzpatrick, J. M., Bellmunt, J., Fizazi, K., Heidenreich, A., Sternberg, C. N., Tombal, B., Alcaraz, A., Bahl, A., Bracarda, S., Di Lorenzo, G., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.03.010 · Cited by 145
“denosumab) or even increase overall survival (OS) (RaCl2 — radium 223 dichloride [Ra223]) [5–13].”
Self-citationThe changing therapeutic landscape of castration-resistant prostate cancer
Yap, T. A., Zivi, A., Omlin, A. G., & Bono, J. S. D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.117 · Cited by 159
Self-citationOvercoming docetaxel resistance in prostate cancer: a perspective review
Hwang, C. (2012) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834012449685 · Cited by 164
Clusterin as a therapeutic target
Wilson, M. R., & Zoubeidi, A. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1267142 · Cited by 144
“Second, there has been a rapid change in the treatment landscape for CRPC with multiple new FDA-approved drugs, such as enzalutamide [142] and abiraterone [143], which in phase III clinical trials extended patient survival by over 4 months.”
BackgroundProstate Cancer Biomarkers: From diagnosis to prognosis and precision-guided therapeutics
Adamaki, M., & Zoumpourlis, V. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107932 · Cited by 157
AKR1C3 as a target in castrate resistant prostate cancer
Adeniji, A. O., Chen, M., & Penning, T. M. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.05.012 · Cited by 143
Recent Advances in the Management of Metastatic Prostate Cancer
Sayegh, N., Swami, U., & Agarwal, N. (2022) · JCO Oncology Practice · doi:10.1200/op.21.00206 · Cited by 142
Kakehi, Y., Sugimoto, M., & Taoka, R. (2017) · International Journal of Urology · doi:10.1111/iju.13380 · Cited by 144
Drug discovery in advanced prostate cancer: translating biology into therapy
Yap, T. A., Smith, A. D., Ferraldeschi, R., Al‐Lazikani, B., Workman, P., & Bono, J. S. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.120 · Cited by 158
Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
Katzenwadel, A., & Wolf, P. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.06.021 · Cited by 152
Androgen receptor antagonists for prostate cancer therapy
Helsen, C., den Broeck, T. V., Voet, A. R. D., Preković, S., Poppel, H. V., Joniau, S., & Claessens, F. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0545 · Cited by 172
“After the efficacy had been proved in clinical trials on both chemotreated and chemonaive mCRPC patients (de Bono et al. 2011, Ryan et al. 2013), the drug was approved by the FDA and EMA for use in patients with mCRPC. Recently, Richards et al. (2012) demonstrated that part of the mechanism of…”
Logothetis, C. J., Gallick, G. E., Maity, S. N., Kim, J., Aparicio, A. M., Efstathiou, E., & Lin, S.-H. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0460 · Cited by 155
“abiraterone (12) or MDV3100 (48), that deplete tumor- produced androgens or inhibit the function of the androgen receptor, respectively, lead to improved clinical outcomes (Figure 2).”
BackgroundSelf-citationDevelopment and prevalence of castration-resistant prostate cancer subtypes
Vellky, J. E., & Ricke, W. A. (2020) · Neoplasia · doi:10.1016/j.neo.2020.09.002 · Cited by 165
“To circumvent this compensation, FDA-approved drug abiraterone acetate is used to inhibit the production of adrenal and intra-tumoral androgens by targeting CYP17, an enzyme involved in androgen steroidogenesis.(40,41) Second-generation AR antagonists and inhibitors of androgen production can be grouped together under…”
MethodManaging bone metastases and reducing skeletal related events in prostate cancer
Gartrell, B. A., & Saad, F. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.70 · Cited by 158
Wardell, S. E., Nelson, E. R., Chao, C. A., & McDonnell, D. P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3771 · Cited by 138
“However, the spectacular clinical responses to Cyp17 inhibitors, such as abiraterone, and to the new high-affinity AR antagonist MDV3100 in late-stage disease, have encouraged a reappraisal of ER as a therapeutic target in those breast cancers that have failed both tamoxifen and aromatase inhibitors (36, 37).”
BackgroundLaere, B. D., van Dam, P., Whitington, T., Mayrhofer, M., Diaz, E. H., den Eynden, G. V., Vandebroek, J., Del‐Favero, J., Laere, S. V., Dirix, L. Y., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.01.011 · Cited by 153
Tumor fraction in cell-free DNA as a biomarker in prostate cancer
Choudhury, A. D., Werner, L., Francini, E., Wei, X. X., Ha, G., Freeman, S. S., Rhoades, J., Reed, S. C., Gydush, G., Rotem, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122109 · Cited by 139
“As in the clinical trials demonstrating a survival benefit to abiraterone (19) and enzalutamide (20), it is standard practice for patients receiving these agents to remain on therapy until clinical or radiographic progression, even when PSA is rising.”
BackgroundMayrhofer, M., De Laere, B., Whitington, T., Van Oyen, P., Ghysel, C., Ampe, J., Ost, P., Demey, W., Hoekx, L., Schrijvers, D., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0595-5 · Cited by 139
Rehman, Y., & Rehman, Y. (2012) · Drug Design Development and Therapy · doi:10.2147/dddt.s15850 · Cited by 151
Hearn, J. W. D., AbuAli, G., Reichard, C. A., Reddy, C. A., Magi‐Galluzzi, C., Chang, K., Carlson, R. E., Rangel, L. J., Reagan, K., Davis, B. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30227-3 · Cited by 147
Badrising, S., van der Noort, V., van Oort, I. M., van den Berg, H. P., Los, M., Hamberg, P., Coenen, J. L., van den Eertwegh, A. J. M., de Jong, I. J., Kerver, E. D., et al. (2014) · Cancer · doi:10.1002/cncr.28518 · Cited by 136
Decoding the androgen receptor splice variants.
Lu, C., & Luo, J. (2013) · PubMed · doi:10.3978/j.issn.2223-4683.2013.09.08 · Cited by 136
“The successful clinical development of these two new agents (14-16) underscores the importance of understanding the mechanism of sustained AR signaling in CRPC.”
Background
Metadata
- Authors
- de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., Staffurth, J. N., Mainwaring, P., Harland, S., Flaig, T. W., Hutson, T. E., Cheng, T., Patterson, H., Hainsworth, J. D., Ryan, C. J., Sternberg, C. N., Ellard, S. L., Fléchon, A., Saleh, M., Scholz, M., Efstathiou, E., Zivi, A., Bianchini, D., Loriot, Y., Chieffo, N., Kheoh, T., Haqq, C. M., & Scher, H. I.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Institut Gustave Roussy (FR)
- Cross Cancer Institute (CA)
- BC Cancer Agency (CA)
- University of Glasgow (GB)
- Institute of Cancer Research (GB)
- Velindre Cancer Centre (GB)
- University College London (GB)
- University of Colorado Cancer Center (US)
- University of Calgary (CA)
- University of California, San Francisco (US)
- Azienda Ospedaliera San Camillo-Forlanini (IT)
- Centre Léon Bérard (FR)
- Georgia Cancer Specialists (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Logothetis, Christopher J.
- Molina, Arturo
- Fizazi, Karim
- North, Scott
- Chi, Kim N.
- Jones, Robert J.
- Goodman, Oscar B.
- Staffurth, John N.
- Mainwaring, Paul
- Flaig, Thomas W.
- Hutson, Thomas E.
- Cheng, Tina
- Hainsworth, John D.
- Ryan, Charles J.
- Sternberg, Cora N.
- Ellard, Susan L.
- Fléchon, Aude
- Saleh, Mansoor
- Efstathiou, Eleni
- Bianchini, Diletta
- Loriot, Yohann
- Kheoh, Thian
- Haqq, Christopher M.
- Scher, Howard I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-05-26
- Volume
- 364
- Issue
- 21
- Pages
- 1995-2005
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3471149
- OpenAlex
- W2110534364
- Cited by
- 4,407
- References
- 54
- Citations by year
- 2026: 111 · 2025: 184 · 2024: 187 · 2023: 209 · 2022: 235 · 2021: 287 · 2020: 290 · 2019: 299 · 2018: 332 · 2017: 322 · 2016: 342 · 2015: 352 · 2014: 384 · 2013: 403 · 2012: 347
- FWCI
- 336.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- RWTH Publications (RWTH Aachen) (submittedVersion)
- Funders
- Prostate Cancer Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Exelixis
- Les Laboratories Pierre Fabre
- NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
- National Institute for Health and Care Research
- Astellas Pharma
- Genentech
- Foundation Medicine
- Medical Research Council
- National Cancer Institute (P50CA092629)
- Cilag
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- abiraterone, metastatic castration-resistant prostate cancer, androgen biosynthesis inhibition, overall survival, docetaxel, prednisone, prostate-specific antigen progression, progression-free survival, fluid retention, hypokalemia, hypertension
- MeSH terms
- Aged, Androgen Antagonists, Androgens, Androstenes, Androstenols, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Fatigue, Humans, Male, Middle Aged, Neoplasm Metastasis, Prednisone, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Survival Analysis, Treatment Outcome, Disease Progression, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.